New must-visit Downtown Panama City businesses
BAY COUNTY, Fla. (WMBB) – If you look past the construction, Downtown Panama City is as cool and creative as ever. You can complete every item on your to-do list without leaving downtown.
Starting with a coffee.
'So my wife is the herbalist, and she's the green thumb plant lady. That's her passion. She's the one who really makes the shop look cool. I'm into coffee and food, and she's into everything else. So, together, I think we make a really good team, and we're just excited to bring our passion here to downtown,' Wild Root owner & operator Eric Marcus said.
With another shop in Lynn Haven, Wild Root owners are excited to have some roots in the downtown community.
Panama City Beach's 7th annual UNwineD event offers food and fun
'We're trying to do things a little bit different. There's a lot of offices here, so we're trying to do a grab-and-go on the menu. We had this item on the menu called Bob Marley, of all things. It is sourdough bread with cottage cheese, apricot jam, a little balsamic glaze, and mold on salt on top of it. It's great,' Marcus said.
While Marcus says there's risk any time you open a business, he's confident the neighborhood's coffee, plant, and food lovers will support the aesthetic shop.
Now that you're caffeinated, it's time to run some errands.
'It's a neighborhood pop-in. It's a place you can go in and grab a roll of toilet paper or some WD-40 or a gift for a baby shower. We have fresh produce, we serve beer and wine, heavy focus on local,' Revival House owner & operator Rachel Davis said.
The Revival House general store opened on March 15th and has already become a go-to spot.
Davis says she hopes the revival house will be a space you can stay for either five minutes or five hours.
'We want it to be a place that people can come in and grab something quick and head to the house or head to a dinner party or had to work or you can sit down and work. You can grab a cup of coffee, you can grab a nice cold beer at the end of your day if you like to,' Davis added.
At this point, you may have enjoyed a draft beer at Revival House and thought, I want another. The Local 115 has local beer, local sports, and oysters.
Owner Kyle Vandergrift says the restaurant and bar pays homage to athletes and coaches who have made a difference in the community over the last 70 years.
Stolen cattle gates lead to arrest of man in Jackson County
If you're looking for some fine wines and more of a gourmet experience, all you have to do is walk around the corner. Upon entering Somethin's Cookin' Downtown, you'll feel like you just stepped into the pages of a cookbook.
'We're going to actually start opening Friday and Saturday for dinner. We're basically a lunch place now, but we do cooking classes, we've got plenty of wine, we do our homemade breads, we got soups, we do wine tastings, probably spring night like every other Thursday night, but Friday and Saturday nights like it just gives you a new opportunity for something else deep in between Ferruccis and a sports bar you know, kind of kind of fit the bill in the middle,' Somethin's Cookin owners & operators Ted & Beth Holland said.
To learn more about Somethin's Cookin' Downtown, click here. For more on Local 115, click here.
For more information on The Revival House General Store, click here. And for Wild Root details, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
16 hours ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Sarepta Therapeutics (SRPT) and Eli Lilly & Co (LLY)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insulet (PODD – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments. Confident Investing Starts Here: Insulet (PODD) In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Insulet. The company's shares closed last Friday at $303.15. According to Marcus is a 4-star analyst with an average return of 9.1% and a 52.8% success rate. Marcus covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Bausch + Lomb Corporation, and Inspire Medical Systems. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insulet with a $337.56 average price target, a 10.9% upside from current levels. In a report issued on June 16, Truist Financial also initiated coverage with a Buy rating on the stock with a $365.00 price target. See Insiders' Hot Stocks on TipRanks >> Sarepta Therapeutics (SRPT) In a report issued on June 20, Anupam Rama from J.P. Morgan maintained a Buy rating on Sarepta Therapeutics, with a price target of $30.00. The company's shares closed last Friday at $20.08. According to Rama has 0 stars on 0-5 stars ranking scale with an average return of -6.9% and a 37.7% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Ultragenyx Pharmaceutical, and Kiniksa Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sarepta Therapeutics with a $44.96 average price target, implying an 115.4% upside from current levels. In a report issued on June 5, Scotiabank also upgraded the stock to Buy with a $80.00 price target. Eli Lilly & Co (LLY) Bernstein analyst Courtney Breen maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1100.00. The company's shares closed last Friday at $762.73. According to Breen is a 2-star analyst with an average return of 0.5% and a 33.3% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $999.57 average price target, implying a 27.2% upside from current levels. In a report issued on June 6, Bank of America Securities also maintained a Buy rating on the stock with a $1000.00 price target.
Yahoo
6 days ago
- Yahoo
The 5 Most Interesting Analyst Questions From Quest's Q1 Earnings Call
Quest Diagnostics delivered a strong start to the year, with revenue and adjusted profit both coming in above Wall Street expectations. Management attributed the robust performance to higher sales volumes, contributions from recent acquisitions, and expanded partnerships with large enterprise accounts. CEO Jim Davis pointed to particularly strong demand in advanced diagnostics, new health plan contracts, and the successful integration of acquired businesses as key factors supporting growth. Davis also highlighted the company's ongoing efforts to improve productivity through increased automation and the deployment of artificial intelligence in laboratory operations. Is now the time to buy DGX? Find out in our full research report (it's free). Revenue: $2.65 billion vs analyst estimates of $2.62 billion (12.1% year-on-year growth, 1.3% beat) Adjusted EPS: $2.21 vs analyst estimates of $2.15 (2.9% beat) Adjusted EPS guidance for the full year is $9.68 at the midpoint, roughly in line with what analysts were expecting Operating Margin: 13%, in line with the same quarter last year Sales Volumes rose 12.4% year on year (1.5% in the same quarter last year) Market Capitalization: $20.33 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Luke Sergott (Barclays) asked about the sustainability of organic volume growth and if recent trends would persist. CEO Jim Davis explained that, after adjusting for weather and leap year effects, volume trends are consistent with the company's expectations and are tracking with late-2024 levels. Kevin Caliendo (UBS) inquired about Quest's tariff exposure and supply chain resilience. Davis stated that less than 1% of supply costs are directly sourced from China and that most critical reagents are U.S.-manufactured, minimizing tariff risks. Patrick Donnelly (Citi) questioned margin pacing for the rest of the year and the performance of LifeLabs. CFO Sam Samad confirmed that margin seasonality is expected to follow historical trends and that LifeLabs is showing steady progress toward corporate margin targets. Noah Kava (Jefferies) sought clarity on the early commercial traction and reimbursement pathway for the Haystack MRD cancer recurrence test. Davis said commercial orders have begun, with reimbursement submissions underway and additional clinical evidence expected in coming quarters. David Westenberg (Piper Sandler) asked about the financial benefits and performance indicators for Quest's collaboration with Google Cloud and use of generative AI. Samad outlined that these efforts will improve data analytics efficiency, support faster customer service, and enable AI-based tools for physicians and patients, with success measured by speed and accuracy of information delivery. In the quarters ahead, the StockStory team will be monitoring (1) the adoption rates of new advanced diagnostic tests such as the AD-Detect Alzheimer's panel and Haystack MRD, (2) progress on integration and margin improvement at recently acquired businesses like LifeLabs, and (3) efficiency gains from automation and Project Nova modernization. The evolution of enterprise partnerships and regulatory updates will also be important signposts for Quest's trajectory. Quest currently trades at $182, up from $161.98 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Yahoo
GOLDFLOWER CANNABIS IS THE EXCLUSIVE FLORIDA HOME OF THE LION ORDER BRAND
MIAMI, June 17, 2025 /PRNewswire/ -- Goldflower Cannabis, one of Florida's fastest-growing vertically integrated cannabis companies, is the proud and exclusive new home to Lion Order, a proprietary cannabis brand led by a collection of professional athletes, activists, and visionaries around the world who seek everlasting change. Created with superstars such as Ray Lewis of the Ravens, Mike James of the Bucs and Lions, Rohan Marley, and Michael Phelps, the brand's launch coincided with the Grand Opening of Goldflower Cannabis's Miami location (7401 Bird Road, Miami) on June 14th. The store also honors Lion Order's South Florida legacy by featuring the state's largest selection of the brand's offerings as well as forthcoming custom art and murals that will make the Goldflower Miami location the spiritual home of Lion Order in Florida. The new partnership reflects a shared commitment to wellness, cultural authenticity, and community empowerment. As a brand, Lion Order draws from the spirit of Rastafari and the legacy of Bob Marley to promote strength, peace, and consciousness through every product. With its Miami flagship store, Goldflower aims to bring these values to a broader audience, connecting local consumers to a lifestyle rooted in purpose and power. "Lion Order isn't just a cannabis brand—it's a mindset," said Rohan Marley, founder of Lion Order and University of Miami football legend. "It's about discipline, integrity, and the courage to stand for what's right. Goldflower gives us the platform to share that message in a powerful way, and Miami is the perfect place to start. This city is vibrant, diverse, and ready to embrace the Lion Order spirit, especially given several of the founders' deep connection with the Miami Hurricanes." The launch of both the Miami store and the Lion Order brand was celebrated at Lincoln's Beard Brewing Company (directly across from the Goldflower Miami location) with a joyous concert by YG Marley, Maffio, and others. The collaboration marks a milestone moment in Florida's cannabis industry and signals a new era of purpose-led retail experiences. For more on Goldflower Cannabis, and to be kept up to date with opening news and brand developments, visit: For more on Lion Order please visit: Disclaimers: Goldflower is a licensed medical marijuana treatment center in the State of Florida. All product names, logos, and brands are property of their respective owners and used under license. Products are intended for medical use only and are available exclusively to qualified patients. This release may contain forward-looking statements and is for informational purposes only. Store opening is subject to regulatory approval. Media Contact: Kayla Sadowsky, kayla@ View original content to download multimedia: SOURCE Goldflower Cannabis
